Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the recruitment of the last patient in its Phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation.
- Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the recruitment of the last patient in its Phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation.
- Patients start treatment with SENS-401 7 days before implantation and continue to receive SENS-401 for a further 42 days.
- The study has been developed with Sensorion’s partner, Cochlear Limited, the global leader in implantable hearing devices.
- The first preliminary efficacy data from this clinical trial were very promising and reinforce our confidence in the potential of SENS-401 in hearing loss prevention."